* Gynecological surgery is associated with a high incidence of postoperative nausea and vomiting. * NK1 receptor antagonists such as aprepitant appear to be highly effective for treating acute and delayed emesis, and yet understanding of the efficacy of different doses of aprepitant is limited. * We performed a prospective, randomized, double-blinded placebo-controlled study of 123 female adults scheduled for laparoscopic hysterectomy who received 80 mg aprepitant, 125 mg aprepitant, or a placebo.
123 female patients (ages 21-60) undergoing laparoscopic hysterectomy 1. 80mg aprepitant 2. 125mg aprepitant 3. placebo Incidences of nausea, vomiting/retching, and use of rescue antiemetics were recorded at 0, 1, 2, 24, and 48 h after surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
150
Aprepitant 80 mg, Aprepitant 125 mg
Gil Medical Center Gachon University
Inchon, South Korea
The numbers (and percentages) of patients who experienced complete response
* The numbers (and percentages) of patients who experienced complete response, i.e. no nausea, retching, vomiting, or need for rescue treatment * required rescue therapy and peak nausea scores * Adverse effects in the three treatment groups
Time frame: 48 hours postoperatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.